UTHR Price Prediction Next Week
Analysis and Insights
Technical Analysis:
United Therapeutics (UTHR) is currently trading at $314, with key technical indicators suggesting a mixed outlook. The Relative Strength Index (RSI) is at 36.17, indicating oversold conditions, which could signal a potential reversal. The MACD is bearish, but the histogram shows signs of stabilization, suggesting a possible trend change.
News Sentiment and Catalysts:
Recent news highlights positive developments for UTHR, including FDA clearance for a clinical trial and strong Q4 earnings. These factors could act as catalysts for a price rebound.
Fibonacci Levels:
The stock is trading near the lower end of its Fibonacci range, with a pivot point at $331.12. The first resistance level is at $354.12, which could act as a target if the stock reverses its current downtrend.
Conclusion:
Based on the oversold RSI and positive news catalysts, UTHR is likely to experience a short-term rebound. The target price for the next trading week is $354, with a BUY recommendation.
UTHR Similar Chart Price Prediction
The price of UTHR is predicted to go up 6.11%, based on the high correlation periods with BGS. The similarity of these two price pattern on the periods is 97.44%.
UTHR
BGS
Up: 6.11%Similarity: 97.44%
UTHR Revenue Forecast
UTHR EPS Forecast
UTHR FAQs
What is UTHR revenue forecast for next quarter？
UTHR VS S&P500
Tyvaso received FDA approval in 2021 for the additional indication of PH-ILD and FDA approval in 2022 for Tyvaso DPI, which further expands Tyvaso's patient reach.
Tyvaso is administered through oral inhalation, and its unique drug/device combination patent means generic companies will need to gain FDA approval for both the inhaler and the generic drug, which complicates bringing generics to market.
Patients on Remodulin are typically the sickest and very sensitive to dose changes, so physicians may be hesitant to switch current patients to generics or branded competitors.
UTHR Analyst's Forecast
Ashwani Verma
UBS
Strong Buy
2025-01-08
Price Target
$415 → $475
Upside
+29.57%
UBS raised the firm's price target on United Therapeutics to $475 from $415 and keeps a Buy rating on the shares as part of a broader note on the U.S. Pharmaceuticals and Biotechnology industry. The firm believes BioPharma will find it difficult to outperform against a more uncertain macro backdrop in the short-term, and thinks President-elect Trump will be capable of enacting significant legislative change, and that unpredictability is expected to cast a shadow over the space, the analyst tells investors in a research note. There will be continued uncertainty in the space until there is more clarity on Trump's changes, UBS says.
Matthew Kaplan
Ladenburg Thalmann
Strong Buy
2024-10-31
Price Target
$319 → $344
Downside
-8.01%
Joseph Thome
TD Cowen
Strong Buy
2024-10-21
Price Target
$350 → $400
Upside
+7.93%
